- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Cellares and TScan to assess automated manufacturing of TSC-101 therapy | 1 | Pharmaceutical Technology | ||
| Mi | Cellares, TScan Partner to Automate Manufacture of TCR-T Candidate | 1 | Contract Pharma | ||
| 22.05. | TScan Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| TSCAN THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 07.05. | TScan Therapeutics GAAP EPS of -$0.22 misses by $0.01, revenue of $1M misses by $1.5M | 1 | Seeking Alpha | ||
| 06.05. | TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Lags Revenue Estimates | 1 | Zacks | ||
| 06.05. | TScan Therapeutics, Inc.: TScan Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update | 183 | GlobeNewswire (Europe) | Early data on patients treated in Cohort C of the ALLOHA Phase 1 heme trial expected in the second quarter of 2026 Initiation of Phase 3 study of TSC-101 (ALLOHA-2) planned for the second quarter... ► Artikel lesen | |
| 06.05. | TScan Therapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 06.05. | TScan Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 27.04. | TScan Therapeutics, Inc.: TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 29th Annual Meeting | 4 | GlobeNewswire (USA) | ||
| 09.04. | H.C. Wainwright bestätigt Kaufempfehlung für Tscan-Aktie mit Kursziel 7 US-Dollar | 4 | Investing.com Deutsch | ||
| 09.04. | H.C. Wainwright reiterates Buy on Tscan stock, $7 target | 3 | Investing.com | ||
| 02.04. | TScan Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 25.03. | Strong Analyst Sentiment on TScan Therapeutics (TCRX) Amid Ongoing Momentum in Cell Therapy Space | 1 | Insider Monkey | ||
| 04.03. | TScan Therapeutics GAAP EPS of -$0.18 beats by $0.06, revenue of $2.57M beats by $0.15M | 1 | Seeking Alpha | ||
| 04.03. | TScan Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 04.03. | TScan Therapeutics, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 04.03. | Earnings Breakdown: TScan Therapeutics Q4 | 1 | Benzinga.com | ||
| 04.03. | TScan Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 26.02. | TScan schließt Patientenrekrutierung ab und erhält FDA-Zulassung für neue Krebstherapien | 3 | Investing.com Deutsch | ||
| 26.02. | TScan completes enrollment in trial cohort, receives FDA clearance | 1 | Investing.com |
1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 77,05 | -1,34 % | BioNTech und BMS melden neue Daten für Lungenkrebskandidat Pumitamig | BioNTech SE und Bristol Myers Squibb haben auf dem ASCO-Jahreskongress in Chicago erste globale Phase-2-Daten für den bispezifischen Immunmodulator Pumitamig in Kombination mit Chemotherapie bei fortgeschrittenem... ► Artikel lesen | |
| MEDIGENE | 0,025 | +5,08 % | PTA-Adhoc: Medigene AG: Widerruf der Zulassung der Aktien der Medigene AG zum Handel im regulierten Markt | DJ PTA-Adhoc: Medigene AG: Widerruf der Zulassung der Aktien der Medigene AG zum Handel im regulierten Markt
Veröffentlichung von Insiderinformationen gemäß Artikel 17 MAR Schlagwort(e): Sonstiges... ► Artikel lesen | |
| AMGEN | 306,30 | +0,97 % | EQS-News: Amgen: Europäische Kommission erteilt Zulassung für Imdylltra von Amgen für die Behandlung von kleinzelligem Lungenkrebs im fortgeschrittenen Stadium | EQS-News: Amgen
/ Schlagwort(e): Sonstiges/Sonstiges
EUROPÄISCHE KOMMISSION ERTEILT ZULASSUNG FÜR IMDYLLTRA VON AMGEN FÜR DIE BEHANDLUNG VON KLEINZELLIGEM... ► Artikel lesen | |
| BIOGEN | 171,56 | +1,19 % | Biogen's Salanersen Wins FDA Breakthrough Therapy Designation For Spinal Muscular Atrophy Treatment | WESTON (dpa-AFX) - Thursday, Biogen Inc. (BIIB) announced that the U.S. Food and Drug Administration has granted salanersen Breakthrough Therapy Designation for the treatment of spinal muscular... ► Artikel lesen | |
| BIOFRONTERA | 2,490 | -3,49 % | BIOFRONTERA AG zeigt bemerkenswerte Stärke | ||
| REGENERON PHARMACEUTICALS | 551,40 | +0,04 % | CytomX Therapeutics Inc.: CytomX Announces Expansion of Strategic Research Collaboration with Regeneron in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer | - Expanded collaboration builds upon research momentum in developing next-generation bispecific immunotherapies using CytomX's PROBODY- and Regeneron's Veloci-Bi- platforms - - CytomX to receive... ► Artikel lesen | |
| EDITAS MEDICINE | 2,340 | -0,43 % | Editas Medicine, Inc.: Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting | CAMBRIDGE, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, shared new preclinical... ► Artikel lesen | |
| LAKEFRONT BIOTHERAPEUTICS | 24,400 | 0,00 % | Gilead Sciences, Inc.: Gilead Sciences and Lakefront Biotherapeutics Complete Acquisition of Ouro Medicines to Further Expand Inflammation Pipeline | - Companies will collaborate on the development of gamgertamig, a potential first-in-class and best-in-class T cell engager in autoimmune diseases -
Gilead Sciences, Inc. (Nasdaq: GILD) and Lakefront... ► Artikel lesen | |
| IMMATICS | 8,350 | -1,82 % | Immatics Presents Clinical Activity and Response Dynamics of Anzu-cel PRAME Cell Therapy at 2026 ASCO Annual Meeting | One-time infusion of anzu-cel (anzutresgene autoleucel, IMA203) PRAME cell therapy induced rapid, deep and durable systemic anti-tumor activity in metastatic PD-1 relapsed cutaneous melanoma and metastatic... ► Artikel lesen | |
| AUTOLUS THERAPEUTICS | 1,340 | +0,75 % | Autolus Therapeutics plc: Autolus Therapeutics Reports First Quarter 2026 Financial Results and Business Updates | AUCATZYL® (obecabtagene autoleucel; obe-cel) net product revenue of $26.2 million for the first quarter of 2026, reflecting strong launches in the US and most recently the UKCompany achieves positive... ► Artikel lesen | |
| ONCOPEPTIDES | 0,159 | +3,04 % | Oncopeptides AB: Oncopeptides signs agreement with Salus for distribution and commercialization of Pepaxti in Central and Eastern Europe | STOCKHOLM, May 26, 2026 - Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces that it has entered into an agreement with SALUS,... ► Artikel lesen | |
| AVACTA | 0,790 | -1,86 % | IN BRIEF: Avacta Group raises GBP9 million for bond repayments | ||
| TANGO THERAPEUTICS | 20,190 | -0,15 % | Tango Therapeutics, Inc.: Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| DERMATA THERAPEUTICS | 1,190 | +0,85 % | Dermata Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | ||
| LYELL IMMUNOPHARMA | 11,950 | -0,17 % | Lyell Immunopharma, Inc: Lyell Immunopharma to Present Phase 1/2 Safety and Translational Data for Ronde-Cel in Large B-Cell Lymphoma at the European Hematology Association 2026 Congress |
Das Unternehmen TSCAN THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -0,23 % bei einem Aktienkurs von 0,980 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TSCAN THERAPEUTICS INC finden Sie auf Wallstreet Online.